As a specialized US-based supplier for institutional labs, PX1 Research provides analytical-grade Bronchogen engineered specifically for in vitro and preclinical cytokine regulation assays. Our synthesized short-chain peptides undergo lot-by-lot HPLC, mass spectrometry, and endotoxin verification to ensure exact sequence fidelity and reproducibility across cellular models.
As a specialized US-based supplier for institutional labs, PX1 Research provides analytical-grade Bronchogen engineered specifically for in vitro and preclinical cytokine regulation assays. Our synthesized short-chain peptides undergo lot-by-lot HPLC, mass spectrometry, and endotoxin verification to ensure exact sequence fidelity and reproducibility across cellular models.
PX1 Research serves as a trusted primary bronchogen cytokine regulation supplier for academic, government, and biotechnology laboratories investigating pulmonary inflammatory cascades. Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide belonging to the class of short-chain Khavinson bioregulators, evaluated in preclinical settings for its capacity to modulate transcription factors involved in inflammatory mediator expression.
When evaluating vendors for research-grade bioregulatory peptides, research institutions require strict lot-to-lot consistency, verifiable purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), and confirmed mass assignment via Electrospray Ionization Mass Spectrometry (ESI-MS). PX1 Research guarantees these parameters for all batches shipped from our ISO 17025-accredited and GMP-compliant testing facilities in California and Arizona.
Bronchogen is a synthetic peptide comprising four amino acid residues: L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-L-leucine ($C_{18}H_{30}N_{4}O_{9}$, MW 446.45 g/mol). Recognized within the broader category of short-chain peptide bioregulators, its design mirrors specific endogenous peptide sequences extracted from bronchial tissue complexes.
The molecular architecture allows the tetrapeptide to interact directly with the nucleosome structure of chromatin in cell-free assays. Bioregulatory models suggest that these short chains fit into specific DNA grooves, altering gene promoter accessibility and subsequent mRNA transcription without modifying the primary genomic sequence.
In vitro data indicate that Bronchogen influences the transcriptional regulation of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). In cultured bronchial epithelial cells and alveolar macrophage lines exposed to lipopolysaccharide (LPS) challenges, treatment with Bronchogen was observed to attenuate nuclear factor kappa B (NF-κB) nuclear translocation.
Preclinical rodent models of acute lung injury have demonstrated that administration of short peptide bioregulators correlates with decreased neutrophil infiltration, lowered myeloperoxidase (MPO) activity, and restored surfactant protein expression. Researchers utilize our high-purity PX1 Research catalog compounds to further map these specific signaling cascades down to individual chemokine receptor expressions.
Within functional peptidomics research, Bronchogen is frequently categorized alongside other tissue-specific peptide complexes. While Bronchogen primarily targets respiratory epithelium and associated immune pathways, parallel compounds demonstrate selectivity for distinct organ systems.
For example, researchers comparative assays often examine Chonluten (Tripeptide Glu-Asp-Gly) alongside Bronchogen to differentiate upper versus lower respiratory tissue responses. Similarly, investigators evaluating systemic immune signaling frequently compare Bronchogen against Thymogen (Glu-Trp) for T-cell maturation markers or Epitalon (Ala-Glu-Asp-Gly) for global cellular senescence models. Sourcing these related peptides from a unified supplier reduces baseline purity variance across comparative datasets.
Cytokine secretion assays, such as multiplex ELISA or flow cytometric bead arrays, are exceptionally sensitive to micro-contaminants. The presence of residual organic solvents, TFA salts, or endotoxins can alter baseline cytokine expression, producing false-positive inflammatory markers in control cultures.
To prevent artifactual data, PX1 Research implements rigorous analytical verification protocols. Every lot of Bronchogen undergoes stringent RP-HPLC to confirm physical purity exceeding 98%, alongside ESI-MS sequence validation. This ensures that observed changes in interleukin production stem directly from peptide-chromatin interaction rather than synthetic impurities.
Because Bronchogen is commonly used in immune cell models, background lipopolysaccharide (LPS) contamination must be completely quantified and constrained. Standard commercial peptide synthesis can introduce trace endotoxins if processing water and equipment are not rigorously controlled.
PX1 Research enforces strict endotoxin testing standards using Chromogenic Recombinant Factor C (rFC) or LAL assays. Our research-grade Bronchogen maintains endotoxin levels strictly below 0.01 EU/mg. This guarantees that macrophage activation or cytokine upregulation observed in experimental groups is not triggered by bacterial contaminants.
Bronchogen is supplied as a lyophilized, sterile-filtered powder to preserve structural integrity during transit and storage. For optimal reconstitution in laboratory environments, researchers should follow standard biochemical protocols tailored to short hydrophobic-hydrophilic mixed tetrapeptides.
Refer to our comprehensive in vitro peptide reconstitution guide for specific concentration calculations. Generally, lyophilized Bronchogen readily dissolves in sterile, deionized water or phosphate-buffered saline (PBS, pH 7.4). For long-term tissue culture assays, reconstituting under laminar flow hoods with filter-sterilized media prevents bacterial or fungal colonization of working stock solutions.
Lyophilized Bronchogen exhibits high stability when stored at -20°C to -80°C in a desiccated environment. Under these conditions, the peptide maintains molecular stability without significant hydrolytic degradation for up to 24 months.
Once reconstituted into aqueous buffers, working aliquots should be stored at -80°C to minimize freeze-thaw cycles, which can induce physical aggregation or subtle peptide bond hydrolysis. PX1 Research ships all orders in protected, temperature-controlled packaging from our distribution centers in California and Arizona, providing same-day dispatch for orders placed before cutoff times Monday through Friday.
PX1 Research supports university laboratories, contract research organizations (CROs), and industrial R&D teams with scalable procurement options. Through our wholesale lab access program, institutions can establish recurring lot reservations, ensuring single-lot continuity across multi-year experimental studies.
Every shipment includes a physical Certificate of Analysis (COA) detailing the specific lot number, mass spec plot, HPLC chromatogram, and endotoxin assay results. By maintaining full supply-chain transparency and US-based manufacturing compliance, PX1 Research provides the reliable foundation necessary for reproducible cytokine regulation research.
What is Bronchogen designated for in a research setting?
Bronchogen is supplied strictly as a research compound for in vitro, biochemical, and preclinical laboratory investigation. It is evaluated primarily for its role in gene expression, chromatin interaction, and cytokine pathway regulation in lung tissue models.
How does PX1 Research verify the purity of Bronchogen?
Every lot of Bronchogen undergoes high-performance liquid chromatography (RP-HPLC) to verify purity (>98%) and mass spectrometry (ESI-MS) to confirm sequence identification and molecular weight. Detailed COAs accompany every batch.
What endotoxin levels are expected in PX1 Research peptides?
PX1 Research enforces strict endotoxin controls, keeping levels below 0.01 EU/mg. This prevents exogenous LPS interference in sensitive cytokine quantification assays.
How should lyophilized Bronchogen be stored upon receipt?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment away from light. Under these conditions, the powder remains stable for up to 24 months.
What solvent is recommended for reconstituting Bronchogen for cell culture?
For most cellular assays, Bronchogen reconstitutes cleanly in sterile, endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4). Once dissolved, solutions should be aliquoted and frozen to avoid repeated freeze-thaw cycles.
How does Bronchogen differ from Chonluten in preclinical studies?
While both are synthetic bioregulatory peptides targeting respiratory pathways, Bronchogen is a tetrapeptide (Ala-Glu-Asp-Leu) whereas Chonluten is a tripeptide (Glu-Asp-Gly). Preclinical assays evaluate them for distinct binding affinities and transcription-modulating profiles.
Are PX1 Research products manufactured in the USA?
Yes. PX1 Research compounds are manufactured in US facilities operating under strict quality protocols, with batch testing verified by independent ISO 17025 accredited laboratories.
Can institutions request bulk quantities for long-term studies?
Yes. Institutional accounts can procure custom bulk lots or reserve specific production batches through the PX1 Research wholesale program to maintain single-lot consistency across multi-phase trials.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.